Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.

ABSTRACT:

Objectives

To evaluate the pharmacokinetics and clinical effectiveness of IV and oral fosfomycin treatment in patients with recurrent urinary tract infection (rUTI) with Escherichia coli.

Patients and methods

Patients with rUTI treated with 3 g of oral fosfomycin every 72 h for at least 14 days were included in a prospective open-label single-centre study. Serum samples were taken after oral and IV administration of fosfomycin. Urine was collected for 24 h on 3 consecutive days. Fosfomycin concentrations in serum and urine were analysed using validated LC-MS/MS. Pharmacokinetics were evaluated using a population model. EudraCT number 2018-000616-25.

Results

Twelve patients were included, of whom nine were also administered IV fosfomycin. Data were best described by a

SUBMITTER: Kuiper SG 

PROVIDER: S-EPMC9297308 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature